BHC
Bausch Health Companies Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$6.56
−2.96%Year over year
Reported trailing growth
- Revenue
- +10.2%
- EBITDA
- -37.4%
- EBIT
- +70.0%
- EPS
- —
- Free cash flow
- +26.2%
- Operating cash flow
- +19.7%
Forward estimates
Based on analyst estimates
- Revenue
- +1.3%
- EBITDA
- +152.3%
- EPS
- +252.5%
Three-year CAGR
- Revenue
- +8.1%
- EBITDA
- +3.4%
- EBIT
- +68.8%
- Net income
- +441.3%
- EPS
- +430.8%
- Free cash flow
- +14.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026